{
  "id": "2247620210_1",
  "title": "辉瑞狩猎时刻已到",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100134991\" data-ratio=\"0.42340425531914894\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sEopW5Xekud7JicHnPibBhUqrlCrCB2npo4f3AJxr0bcbc9URAQ6yZIsCicGUFjgx2y0wPet197e9kw/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   当前制药行业竞争激烈，药企面临着诸多挑战。如何\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    实现业绩的持续增长\n   </span>\n   ，成为了各大药企亟待解决的问题。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   2024 年，辉瑞凭借\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    外延式扩张战略\n   </span>\n   实现总营收 636.27 亿美元，在\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    全球制药巨头中排名第一\n   </span>\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （按制药业务）\n   </span>\n   ，重新夺回了「宇宙第一大药厂」的宝座。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   然而，辉瑞股价却一直跌跌不休\n  </span>\n  <span leaf=\"\" style='line-height: 1.75em;color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   ，截至 6 月 17 日收盘，总市值达 1364.49 亿美元，市盈率\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （TTM）\n   </span>\n   为 17.31 倍。\n  </span>\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   反过来，营收规模不及辉瑞的礼来、艾伯维、阿斯利康等 MNC 巨头的总市值和市盈率均高于辉瑞。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-bottom: 8px;margin-left: 8px;margin-right: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100136558\" data-ratio=\"0.537962962962963\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGlSbGibbuuXlRuCgkB1iaCMP0zY9gYf5673QYhb4PbFeBDEc7sFyTWLS0A/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mc1tz44t17cx\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mc1tz43vsi6\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;font-size: 12px;\">\n  <span leaf=\"\">\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    来源：辉瑞官网\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   究其原因，是由于辉瑞有\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    诸多重磅产品面临专利悬崖危机\n   </span>\n   ，急需更多产品填补营收缺口。这也是辉瑞宣布 2025 年计划投入 100-150 亿美元用于并购交易的原因。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;margin-bottom: 0px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 17px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;line-height: 1.75em;letter-spacing: 0.034em;font-style: normal;font-weight: normal;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;'>\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100005471\" data-ratio=\"0.09166666666666666\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSNVoeeMhPsWC6JvHGAhMNaWpTzd5Xup3rRSuibpcdEn0bBBx30uuEsKw/640?wx_fmt=png\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mbulawbw1n7s\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbulawayc6r\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;font-size: 16px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    对抗专利悬崖危机\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    外延式扩张战略\n   </span>\n   是辉瑞实现业绩增长的关键引擎，这点可以从财报得到验证。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   2024 年，辉瑞实现总营收同比增长 7% 至 636.27 亿美元。其中，基础护理、专科护理、肿瘤三大业务板块，分别实现收入 301.35 亿美元\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （-2%）\n   </span>\n   、166.52 亿美元\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （+11%）\n   </span>\n   、\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    156.12 亿美元\n   </span>\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （+25%）\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   而肿瘤业务之所以能实现如此强劲的增长，离不开\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    外部产品的贡献\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   要知道，辉瑞在肿瘤领域面临严峻的专利悬崖危机，其中重磅产品 Palbociclib\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （Ibrance，哌柏西利）\n   </span>\n   因专利到期销售额下滑，2024 年同比减少 8% 至 43.67 亿美元。\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100136556\" data-ratio=\"0.5768518518518518\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8sfrH2Fh8k0NTibfMoWpicnGl6xSsSk69F8ALq8bJFFH76LBmUAibhujL7R7cmJ7UMvmWO8iafS2LQ6gg/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <section data-mpa-action-id=\"mc1t6mw2unw\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mc1t6mvgvgc\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;font-size: 12px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    来源：Insight 数据库\n   </span>\n  </span>\n </section>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   不过，辉瑞豪掷 430 亿美元收购 Seagen 所获得的多款产品，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    在 2024 年实现收入合计约 33 亿美元\n   </span>\n   ，贡献肿瘤业务 21% 的收入。其中，Padcev\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （Nectin-4 ADC）\n   </span>\n   、Adcetris\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （CD30 ADC）\n   </span>\n   、Tivdak\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （TF ADC）\n   </span>\n   、Tukysa\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （HER2 抑制剂）\n   </span>\n   分别实现收入 15.88 亿美元、10.89 亿美元、1.31 亿美元、4.8 亿美元。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   同期，辉瑞与安斯泰来联合开发的前列腺癌药物 Xtandi\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （恩扎卢胺）\n   </span>\n   ，实现销售额同比增长 23% 至 20.39 亿美元。\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    得益于这些通过收购或授权引入的非自研产品\n   </span>\n   ，成功弥补了 CDK4/6 抑制剂哌柏西利销售额下滑的影响。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   2024 年，辉瑞还有不少外部产品贡献了可观的收入，包括：\n  </span>\n </p>\n <ul class=\"list-paddingleft-1\" style=\"margin-left: 8px;margin-right: 8px;\">\n  <li>\n   <p style=\"line-height: 1.75em;\">\n    <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n     与百时美施贵宝联合开发的 Eliquis（阿哌沙班），销售 73.66 亿美元，同比增长 9%；\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;\">\n    <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n     豪掷 680 亿美元收购惠氏获得的 Prevnar family 肺炎球菌疫苗（Prevnar 20&amp;13）、Enbrel（美国和加拿大以外的市场），分别收入 64.11 亿美元、6.9 亿美元；\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;\">\n    <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n     斥资 116 亿美元收购 Biohaven 获得的偏头痛药物 Rimegepant（瑞美吉泮），实现收入同比增长 36% 至 12.63 亿美元；\n    </span>\n   </p>\n  </li>\n  <li>\n   <p style=\"line-height: 1.75em;margin-bottom: 24px;\">\n    <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n     斥资 140 亿美元收购 Medivation 获得的 PARP 抑制剂 Talzenna（他拉唑帕利），实现收入同比增长 83% 至 1.17 亿美元。\n    </span>\n   </p>\n  </li>\n </ul>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   综上可见，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    外部引进产品不仅成为辉瑞业绩增长的核心引擎，更是其对抗专利悬崖、填补管线断层的战略利器\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   值得注意的是，辉瑞未来三年将有 8 个重磅产品的专利集中到期，包括 Inlyta、Xeljanz、Prevnar 13、Eliquis、Ibrance、Xtandi、Vyndaqel、Mektovi，这些重磅产品 2024 年实现收入合计达 250 亿美元，占公司总营收比重高达 40%。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   很显然，仅仅依靠现有产品和内生增长无法填补巨大的营收缺口。基于此，辉瑞宣布了未来的发展战略：\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    2025 年计划投入 100-150 亿美元用于并购交易\n   </span>\n   ，重点将放在\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    增强研发管线\n   </span>\n   ，而非仅仅追求短期的收入增长。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;margin-bottom: 0px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 17px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;line-height: 1.75em;letter-spacing: 0.034em;font-style: normal;font-weight: normal;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;'>\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100005464\" data-ratio=\"0.09166666666666666\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSmkuYSKhxoZteNgXZAE0DDTL8Z3ibib4fSdyDObP4fGvLA9kFx8xacllw/640?wx_fmt=png\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mbulbgwg17oc\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbulbgvi1kv9\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;font-size: 16px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    「买买买」模式开启\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mbum8xhv1oss\" data-pm-slice=\"0 0 []\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span leaf=\"\">\n    在超百亿美金预算的支持下，辉瑞开启了「买买买」模式。今年 5 月，辉瑞斥资超 60 亿美元\n    <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n     （其中首付款 12.5 亿美元）\n    </span>\n    引进了三生制药的 PD-1/VEGF 双抗 SSGJ-707。\n   </span>\n   <span mpa-font-style=\"mbum8xgsjeu\" style=\"font-size: 12px;\">\n    <span data-mpa-action-id=\"mbum8xgs41r\" leaf=\"\">\n     <br/>\n    </span>\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   辉瑞之所以选择重金押注\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"p\",\"attributes\":{},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   SSGJ-707\n  </span>\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   ，一方面是看中 PD-(L)1/VEGF 双抗的临床价值和市场前景。毕竟，康方生物的依沃西单抗在头对头试验中击败了全球药王 K 药。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   另一方面，SSGJ-707 已处于Ⅲ期临床，进度在全球排名第二，并且展现出了同类最佳潜力。最关键的是，PD-1/VEGF 双抗还有\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    与 ADC 联合用药的潜力\n   </span>\n   ，SSGJ-707 正在开展联用百利天恒 BL-B01D1\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （EGFR/HER3 ADC）\n   </span>\n   治疗实体瘤的临床试验。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   要知道，辉瑞通过自研和引进已经打造了丰富的 ADC 管线矩阵，目前\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    有 7 款ADC 产品上市，后续还有 20 多款在研\n   </span>\n   ，覆盖近 10 个不同靶点。此次合作，SSGJ-707 将成为辉瑞肿瘤管线的基石用药，与 ADC 产品组合形成强大的协同效应。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;margin-bottom: 8px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   辉瑞已上市的 ADC 产品\n  </span>\n </p>\n <section nodeleaf=\"\" style=\"text-align: center;margin-bottom: 8px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100136316\" data-ratio=\"0.9121114683815649\" data-s=\"300,640\" data-type=\"png\" data-w=\"933\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8veEoaITIYHQKpWAydG8Fv21kXAeLpSUs5VRMibKRv7zicib6Thykz10aSQXicrReolORHgDSX5RqbT4w/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mbum7u79uv8\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbum7u731hsd\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;font-size: 12px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    来源：Insight 数据库\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   正如辉瑞董事长兼 CEO Albert Bourla 在近期举行的 Goldman Sachs 全球健康医疗会议上表示：「PD-1/VEGF 双抗是过去十年中唯一一个显示出优于 PD-1 的类别。对于任何 PD-1 药物，将 ADC 与 PD-1 组合使用，疗效远优于单药治疗。鉴于我们拥有所有 ADC，将新的、可以说是标准的免疫疗法纳入我们的产品组合具有重要的战略意义。」\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   辉瑞预计今年的并购规模预算高达 100 亿美元到 150 亿美元，到\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    目前为止已经达成了 5 笔交易，但只花了不到 20 亿美元\n   </span>\n   ，后续用于 BD 的资金还很充裕。不过，Albert Bourla 表示，尽管手握 150 亿美金，但基于高溢价，不会做一笔 150 亿美元的交易，而是做几笔规模较小的交易。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;text-align: center;margin-bottom: 24px;\">\n  <span data-mpa-action-id=\"mbum8xhv1oss\" data-pm-slice=\"0 0 []\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span data-pm-slice='2 2 [\"para\",{\"tagName\":\"p\",\"attributes\":{\"style\":\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"},\"node\",{\"tagName\":\"span\",\"attributes\":{\"style\":\"color: rgba(0, 0, 0, 0.9); font-size: 15px; font-family: mp-quote, \\\"PingFang SC\\\", system-ui, -apple-system, BlinkMacSystemFont, \\\"Helvetica Neue\\\", \\\"Hiragino Sans GB\\\", \\\"Microsoft YaHei UI\\\", \\\"Microsoft YaHei\\\", Arial, sans-serif; letter-spacing: 0.034em; font-style: normal; font-weight: normal;\",\"data-mpa-action-id\":\"mbum8xhv1oss\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' mpa-font-style=\"mbum8xgsjeu\" style=\"font-size: 12px;\">\n    <span leaf=\"\">\n     <img class=\"rich_pages wxw-img\" data-imgfileid=\"100136320\" data-ratio=\"0.48703703703703705\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8veEoaITIYHQKpWAydG8Fv2DjlMtcX2v0mHe9AmFHC6wkXQysmdpGpCiaJOgt0DbhBVNnQCoXw3TFQ/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\"/>\n     <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n      来源：Insight 数据库\n     </span>\n    </span>\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   哪些领域是辉瑞可能 BD 的方向？\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   早在今年 3 月举办的 BIOCHINA2025 主旨论坛上，来自辉瑞总部的 Shaan Gandhi 表示，将聚焦六大领域，包括\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    肿瘤学、抗感染药、炎症与免疫学、疫苗、罕见疾病和内科医学\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   在近期高盛全球医疗健康年会上，Albert Bourla 明确表示，「我们对心脏代谢和肥胖领域更感兴趣，比如内科正在关注。肥胖领域存在着巨大的未满足医疗需求。现在也有很多新兴的参与者。尤其是在中国，有大量关于肥胖方面的科学研究。」\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;margin-bottom: 8px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 17px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;line-height: 1.75em;letter-spacing: 0.034em;font-style: normal;font-weight: normal;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;'>\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100005463\" data-ratio=\"0.09166666666666666\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSgmzgu7wuUwYWH5bAUemnew7uoSV2mZ3rGslAnnpoyBGZySianhBRh6A/640?wx_fmt=png\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mbulbxfd2191\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbulbxee1er1\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;font-size: 16px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    BD 方向展望\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   显然，\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    肥胖领域是辉瑞高概率 BD 的方向\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   尽管此前口服 GLP-1 减肥药接连折戟，但辉瑞还未彻底放弃，毕竟内科管线还比较薄弱，目前主要聚焦 MASH、心衰、肥胖等疾病，尤其肥胖领域的靶点布局为内卷严重的 GLP-1，且研发进度显著落后同行\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （仍处于临床 Ⅰ 期）\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   按照 Albert Bourla 的口径，辉瑞将有望从中国引进减肥药管线。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   此前，中国药企已有多款减重管线达成 BD 交易，包括阿斯利康以超 20 亿美元引进诚益生物口服 GLP-1R 激动剂 ECC5004、恒瑞医药将口服小分子 HRS-7535 等 GLP-1 产品组合以超 60 亿美元授权出海、诺和诺德以 20 亿美元引进联邦制药 GLP-1R/GIPR/GCGR 三靶点激动剂 UBT251、再生元以超 20 亿美元引进翰森制药 GLP-1/GIP 双受体激动剂 HS-20094。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   归纳来看，上述交易主要集中于\n   <span style=\"color: rgb(0, 0, 0);font-weight: bold;\" textstyle=\"\">\n    GLP-1 多靶点药物及口服制剂\n   </span>\n   ，体现出差异化布局策略。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   Insight 数据库显示，当前国内在研的 GLP-1 双靶点药物管线已超过 20 款，其中信达生物的玛仕度肽进度最快，有望今年获批上市；已进入临床阶段的管线，还有博瑞医药 BGM0504、众生药业子公司众生睿创的 RAY1225 等。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   相较之下，国内在研的 GLP-1 三靶点药物管线不多，已进入临床阶段的包括民为生物的 MWN109\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （全球首创口服 GLP-1/GIP/GCG 激动剂）\n   </span>\n   和 MWN105\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （全球首创 GLP-1/GIP/FGF21 三靶点激动剂）\n   </span>\n   、华东医药控股子公司道尔生物的 DR10624\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （全球首创 FGF21R/GLP-1R/GCGR 长效三重激动剂）\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   另外，已公布临床数据但未达成 BD 交易的国产 GLP-1 小分子药物，包括：华东医药 HDM1002、歌礼制药 ASC30、德睿智药 MDR-001、锐格医药 RGT-075、硕迪生物 GSBR-1290 等。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   此外，辉瑞的并购和 BD 触角或将\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    延伸至更多创新赛道\n   </span>\n   。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   辉瑞此前表示，更倾向于收购早期管线，并购战略将逐步转向长期研发布局，重点增强公司在未来几年内有潜力的研发领域，而非追求短期的收益。例如，辉瑞在 2021 年以高达 24 亿美元的总交易额获得潜在全球首款 PROTAC 药物 Vepdegestrant\n   <span style=\"color: rgb(178, 178, 178);\" textstyle=\"\">\n    （ARV-471）\n   </span>\n   的全球权益，便是「押注未来」的体现。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   这预示着，在基因编辑、AI 制药、基因与细胞疗法、mRNA 技术、新型疫苗等前沿技术领域，辉瑞或将延续其前瞻性布局策略。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <br/>\n  </span>\n </p>\n <section nodeleaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 17px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;line-height: 1.75em;letter-spacing: 0.034em;font-style: normal;font-weight: normal;margin-left: 8px;margin-right: 8px;margin-bottom: 8px;'>\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100005465\" data-ratio=\"0.09166666666666666\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSKQwRwbhV9O0jCwwEFiaNIvgY1P0uucGQcA5k8X7QeszSSial2LzVO69Q/640?wx_fmt=png\" style=\"height: auto !important;\" type=\"block\"/>\n </section>\n <p data-mpa-action-id=\"mbulc3ao1r1o\" data-pm-slice=\"0 0 []\" mpa-font-style=\"mbulc39p81h\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;font-size: 16px;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   <span style=\"color: rgb(0, 180, 200);font-weight: bold;\" textstyle=\"\">\n    结语\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   尽管辉瑞以 636 亿美元总营收重夺全球药企榜首，但其总市值和市盈率却低于营收规模更小的 MNC 巨头，反映出市场对其专利悬崖危机的深度忧虑。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   目前，为了填补营收缺口，辉瑞正在推进外延式扩张战略，祭出「并购+BD」组合拳，开启「买买买」模式。\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;\">\n  <span data-mpa-action-id=\"mbul9tynp0l\" leaf=\"\" style='color: rgba(0, 0, 0, 0.9);font-size: 15px;font-family: mp-quote, \"PingFang SC\", system-ui, -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.034em;font-style: normal;font-weight: normal;'>\n   不过，辉瑞能否扭转投资者预期、提振股价，取决于两点：能否\n   <span style=\"font-weight: bold;\" textstyle=\"\">\n    通过 BD 快速填补营收缺口，以及并购管线临床转化效率\n   </span>\n   。\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;text-align: left;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;color: rgb(163, 163, 163);\">\n     <span leaf=\"\">\n      封面来源：\n     </span>\n    </span>\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;\">\n     <span style=\"color:#b2b2b2;\">\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;\">\n    <span style=\"color:#b2b2b2;\">\n     <span leaf=\"\">\n      企业logo\n     </span>\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 15px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。\n    </span>\n   </span>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: system-ui, -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: left;visibility: visible;line-height: 1.75em;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      编辑：月牙\n     </span>\n     <span leaf=\"\">\n      <br/>\n     </span>\n    </span>\n   </strong>\n  </span>\n </p>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </p>\n <section style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;text-align: left;line-height: 1.75em;margin-bottom: 24px;'>\n  <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"-webkit-tap-highlight-color: transparent;outline: 0px;visibility: visible;\">\n    <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"-webkit-tap-highlight-color: transparent;outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </section>\n <section style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <span leaf=\"\">\n   <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133276\" data-ratio=\"0.6319148936170212\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vJ9AD3IliaMYHfGS36BCmzgFCmSaH97qfZGwxsicbb6ibA9sP4ZA3JVDDCSaEhHfHBD0nh8TMftib9UQ/640?wx_fmt=png&amp;from=appmsg\" style=\"height: auto !important;\"/>\n   <img class=\"rich_pages wxw-img\" style=\"height: auto !important;\"/>\n  </span>\n </section>\n <p style='-webkit-tap-highlight-color: transparent;margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;caret-color: rgba(0, 0, 0, 0);color: rgb(34, 34, 34);font-family: -apple-system-font, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);text-align: center;line-height: 1.75em;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </p>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1750293000,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8veEoaITIYHQKpWAydG8Fv2SreBTe9I8QUfJke1YPj6H2YArvhsPAuMZvweu9ZluKdibgVbJOBxowA/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}